Literature DB >> 9933046

Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting.

N R Netto1, M L de Lima, M R Netto, C A D'Ancona.   

Abstract

OBJECTIVES: To examine the variability of bladder outlet obstruction and mild lower urinary tract symptoms in patients with benign prostatic hyperplasia (BPH) followed up by watchful waiting.
METHODS: The International Prostate Symptom Score (IPSS) has four questions related to voiding symptoms and three related to filling symptoms. Scores of 0 to 7, 8 to 19, and 20 to 35 represent mild, moderate, and severe symptoms, respectively. Over a period of 36 months the IPSS questionnaire was administered to 479 patients 50 to 81 years old (mean age 63) with BPH. A pressure-flow study was used to determine the presence of bladder outlet obstruction. On the basis of their scores, the patients were classified into 50 with mild, 227 with moderate, and 202 with severe symptoms. In the present study only patients with a mild score were analyzed.
RESULTS: Of 50 patients with mild symptoms, 16 (32%) had bladder outlet obstruction. After a period of 9 to 22 months (mean 17) of watchful waiting, these 16 patients were reviewed. Twelve (75%) of the 16 had bladder outlet obstruction reconfirmed by pressure-flow studies, and 3 (18.8%) of 16 had increased symptoms (moderate symptomatic) and underwent treatment (1 began pharmacologic treatment, and 2 chose transurethral resection). A total of 4 (25%) of 16 patients still had mild voiding disturbances and refused the second urodynamic evaluation. The remaining 34 patients with no obstruction had annual routine follow-up and had persistent mild symptom scores and normal uroflowmetric results. These patients did not undergo another pressure-flow evaluation.
CONCLUSIONS: A pressure-flow study is routinely avoided in patients with a mild IPSS. From symptoms alone it was not possible to diagnose bladder outlet obstruction in these patients. Pressure-flow studies and symptom profiles measure different aspects of the clinical condition. After a mean follow-up of 17 months of watchful waiting, 13 (81.2%) of 1 6 patients were clinically stable. Because the need for therapy is dictated by quality of life, it is difficult to propose treatment for patients with minimal symptoms, even in the presence of bladder outlet obstruction.

Entities:  

Mesh:

Year:  1999        PMID: 9933046     DOI: 10.1016/s0090-4295(98)00475-0

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Free uroflowmetry versus "Do-It-Yourself" uroflowmetry in the assessment of patients with lower urinary tract symptoms.

Authors:  Gabriella Mombelli; Stefano Picozzi; Giovanni Messina; Dario Truffelli; Carlo Marenghi; Gabriele Maffi; Luca Carmignani
Journal:  Int Urol Nephrol       Date:  2014-05-18       Impact factor: 2.370

Review 2.  Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Jiye Kim; Roderick MacDonald; Balaji Reddy; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2017-11-22

Review 3.  Current Treatment for Benign Prostatic Hyperplasia.

Authors:  Arkadiusz Miernik; Christian Gratzke
Journal:  Dtsch Arztebl Int       Date:  2020-12-04       Impact factor: 5.594

Review 4.  Korean clinical practice guideline for benign prostatic hyperplasia.

Authors:  Jeong Kyun Yeo; Hun Choi; Jae Hyun Bae; Jae Heon Kim; Seong Ok Yang; Chul Young Oh; Young Sam Cho; Kyoung Woo Kim; Hyung Ji Kim
Journal:  Investig Clin Urol       Date:  2016-01-11

5.  Correlation of tools for objective evaluation of infravesical obstruction of men with lower urinary tract symptoms.

Authors:  Orestes Mazzariol; Leonardo O Reis; Paulo R Palma
Journal:  Int Braz J Urol       Date:  2019 Jul-Aug       Impact factor: 1.541

6.  Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.

Authors:  Eu Chang Hwang; Shreyas Gandhi; Jae Hung Jung; Mari Imamura; Myung Ha Kim; Ran Pang; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2018-10-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.